{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:31:15Z","timestamp":1793712675713,"version":"4.6.1"},"reference-count":278,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100030989","name":"National Ilan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030989","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","award":["NRMC\/CSAINV22jul-0004"],"award-info":[{"award-number":["NRMC\/CSAINV22jul-0004"]}],"id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","award":["NMRC\/CIRG21nov-0023"],"award-info":[{"award-number":["NMRC\/CIRG21nov-0023"]}],"id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Retinal and Eye Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.preteyeres.2025.101380","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T02:42:47Z","timestamp":1750473767000},"page":"101380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Immunomodulatory therapy in non-infectious Uveitis: Current landscape, gaps, and future directions"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-5850","authenticated-orcid":false,"given":"Rupesh","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Yao","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Rojas-Carabali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Cifuentes-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Sanjay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Yu-Hor Thong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra","family":"de-la-Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Michael","family":"Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotirmay","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Patrick","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.preteyeres.2025.101380_bib1","series-title":"Statpearls","article-title":"Secukinumab","author":"Aboobacker","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1080\/09273948.2020.1820531","article-title":"Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with vogt-koyanagi-harada disease","volume":"30","author":"Abu El-Asrar","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaophthalmol.2013.4237","article-title":"Incidence and prevalence of uveitis: results from the Pacific ocular inflammation study","volume":"131","author":"Acharya","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2023.04.011","article-title":"Intravitreal therapy for uveitic macular edema-ranibizumab versus methotrexate versus the dexamethasone implant: the MERIT trial results","volume":"130","author":"Acharya","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(24)02468-1","article-title":"Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial","volume":"405","author":"Acharya","year":"2025","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.preteyeres.2025.101380_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/tvst.5.4.7","article-title":"Choroidal vascularity index in vogt-koyanagi-harada disease: an EDI-OCT derived tool for monitoring disease progression","volume":"5","author":"Agrawal","year":"2016","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib7","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jamaophthalmol.2017.4485","article-title":"Clinical features and outcomes of patients with tubercular uveitis treated with antitubercular therapy in the collaborative ocular tuberculosis study (COTS)-1","volume":"135","author":"Agrawal","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib8","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/cas.13012","article-title":"High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma","volume":"107","author":"Akiyama","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.preteyeres.2025.101380_bib9","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3109\/09273948.2013.779727","article-title":"Long-term clinical outcomes in patients with refractory uveitis associated with beh\u00e7et disease treated with infliximab","volume":"21","author":"Al Rashidi","year":"2013","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/09273948.2018.1453524","article-title":"Efficacy and safety of mycophenolate mofetil in the treatment of recalcitrant intermediate uveitis","volume":"27","author":"Ali","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib12","article-title":"The autoimmune tautology: from polyautoimmunity and familial autoimmunity to the autoimmune genes","volume":"2012","author":"Anaya","year":"2012","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib13","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus And\/Or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/OPTH.S2452","article-title":"A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (lux uveitis multicenter investigation of a new approach to treatment) trials of steroid-sparing voclosporin","volume":"2","author":"Anglade","year":"2008","journal-title":"Clin. Ophthalmol. Auckl. NZ"},{"key":"10.1016\/j.preteyeres.2025.101380_bib15","series-title":"Statpearls","article-title":"Tacrolimus","author":"Araya","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib16","first-page":"501","article-title":"Comprehensive microRNA analyses using vitreous humor of ocular sarcoidosis","volume":"263","author":"Asakage","year":"2025","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib17","doi-asserted-by":"crossref","first-page":"e371","DOI":"10.1016\/S2665-9913(21)00069-2","article-title":"Biomarkers of tolerance in immune-mediated inflammatory diseases: a new era in clinical management?","volume":"3","author":"Baker","year":"2021","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2165\/00002018-200124090-00002","article-title":"Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management","volume":"24","author":"Behrend","year":"2001","journal-title":"Drug Saf."},{"key":"10.1016\/j.preteyeres.2025.101380_bib19","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib20","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib21","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/09273948.2021.1880604","article-title":"Efficacy of rituximab treatment in vogt-koyanagi-harada disease poorly controlled by traditional immunosuppressive treatment","volume":"30","author":"Bolletta","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib22","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1136\/ard-2024-225933","article-title":"Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b\/3 trials","volume":"83","author":"Brown","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib23","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2024.4674","article-title":"Integrating N-of-1 trials into learning health care systems","author":"Brown","year":"2025","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib24","article-title":"Use of immunosuppression and subsequent cancer incidence: cohort study","volume":"2","author":"Buchanich","year":"2023","journal-title":"BMJ Oncol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.39940","article-title":"Anti\u2013Interleukin\u20106 receptor tocilizumab for severe juvenile idiopathic arthritis\u2013associated uveitis refractory to anti\u2013tumor necrosis factor therapy: a multicenter study of twenty\u2010five patients","volume":"69","author":"Calvo\u2010R\u00edo","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajo.2015.12.032","article-title":"Rituximab in the treatment of refractory noninfectious scleritis","volume":"164","author":"Cao","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib27","article-title":"Two-arm crossover randomized controlled trial versus meta-analysis of N-of-1 studies: Comparison of statistical efficiency in determining an intervention effect","volume":"67","author":"Carrozzo","year":"2025","journal-title":"Biom. J. Biom. Z."},{"key":"10.1016\/j.preteyeres.2025.101380_bib28","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s10067-014-2781-1","article-title":"Long-lasting uveitis remission and hearing loss recovery after rituximab in vogt-koyanagi-harada disease","volume":"34","author":"Caso","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib29","first-page":"S234","article-title":"Nephrotoxic aspects of cyclosporine. Transplant","volume":"36","author":"Cattaneo","year":"2004","journal-title":"SAVE Proc."},{"key":"10.1016\/j.preteyeres.2025.101380_bib30","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/112067210901900117","article-title":"Induction of durable remission in ocular inflammatory diseases","volume":"19","author":"Cervantes-Castaneda","year":"2009","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09273948.2024.2408401","article-title":"Biological and therapeutic role of Interleukin-6 in non-infectious uveitis: a narrative review","author":"Cifuentes-Gonz\u00e1lez","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/717598","article-title":"Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience","volume":"2014","author":"Cordero-Coma","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib33","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41584-020-0373-9","article-title":"Methotrexate and its mechanisms of action in inflammatory arthritis","volume":"16","author":"Cronstein","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1186\/s12967-024-05925-x","article-title":"Identifying prioritization of therapeutic targets for ankylosing spondylitis: a multi-omics Mendelian randomization study","volume":"22","author":"Dai","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib35","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib36","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/rheumatology\/kez449","article-title":"The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data","volume":"59","author":"Davies","year":"2020","journal-title":"Rheumatol. U. K."},{"key":"10.1016\/j.preteyeres.2025.101380_bib37","series-title":"Medical Genetics Summaries","article-title":"Azathioprine therapy and TPMT and NUDT15 genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.preteyeres.2025.101380_bib38","first-page":"91","article-title":"Anti-Interleukin-6 antibodies for autoimmune retinopathy with macular edema. Ophthalmol","volume":"6","author":"Deaner","year":"2022","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101380_bib39","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr2.11139","article-title":"Incidence of uveitis in secukinumab-treated patients with ankylosing spondylitis: pooled data analysis from three phase 3 studies","volume":"2","author":"Deodhar","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib40","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","article-title":"Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study","volume":"26","author":"Deuter","year":"2006","journal-title":"Retina Phila. Pa"},{"key":"10.1016\/j.preteyeres.2025.101380_bib41","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.preteyeres.2025.101380_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4161\/mabs.2.1.10328","article-title":"Canakinumab","volume":"2","author":"Dhimolea","year":"2010","journal-title":"mAbs"},{"key":"10.1016\/j.preteyeres.2025.101380_bib43","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib44","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for UveitiS (FOCUS) initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib45","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2290365","article-title":"The efficacy of immunosuppressive drugs induction therapy for lupus nephritis: a systematic review and network meta-analysis","volume":"45","author":"Dong","year":"2023","journal-title":"Ren. Fail."},{"key":"10.1016\/j.preteyeres.2025.101380_bib46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.preteyeres.2025.101380_bib47","series-title":"Statpearls","article-title":"Uveitis","author":"Duplechain","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib48","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib49","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/09273948.2015.1134581","article-title":"Adalimumab for ocular inflammation","volume":"25","author":"Durrani","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib50","series-title":"Statpearls","article-title":"Adalimumab","author":"Ellis","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib51","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1007\/s10792-021-01851-9","article-title":"Protective effect of filgotinib in rat endotoxin-induced uveitis model","volume":"41","author":"Erda\u011f","year":"2021","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib52","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10067-016-3506-4","article-title":"Interleukin (IL)-1 inhibition with anakinra and canakinumab in Beh\u00e7et\u2019s disease-related uveitis: a multicenter retrospective observational study","volume":"36","author":"Fabiani","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/09273948.2017.1351573","article-title":"Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with beh\u00e7et\u2019s disease","volume":"27","author":"Fabiani","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8294560","article-title":"New potential weapons for refractory scleritis in the era of targeted therapy","volume":"2020","author":"Fabiani","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib55","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ajo.2017.03.001","article-title":"Interferon-alpha2a and systemic corticosteroid in monotherapy in chronic uveitis: results of the randomized controlled BIRDFERON study","volume":"177","author":"Fardeau","year":"2017","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib56","series-title":"Statpearls","article-title":"Infliximab","author":"Fatima","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib57","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/APO.0000000000000371","article-title":"Biologic drugs for the treatment of noninfectious uveitis","volume":"10","author":"Ferreira","year":"2021","journal-title":"Asia-Pac. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib58","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/112067210701700110","article-title":"Long-term follow-up of tacrolimus treatment in immune posterior uveitis","volume":"17","author":"Figueroa","year":"2007","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/bjo-2023-324927","article-title":"Treatment exit options for non-infectious uveitis registry: participant characteristics at 3 years","volume":"109","author":"Fink","year":"2024","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib60","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/acr.22613","article-title":"Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in pediatric rheumatology registry","volume":"67","author":"Foeldvari","year":"2015","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.preteyeres.2025.101380_bib62","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib63","article-title":"The future of pharmaceuticals: artificial intelligence in drug discovery and development","author":"Fu","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.preteyeres.2025.101380_bib64","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MOT.0000000000000771","article-title":"Recent advances in precision medicine for individualized immunosuppression","volume":"25","author":"Fu","year":"2020","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.preteyeres.2025.101380_bib65","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s13346-020-00843-z","article-title":"Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives","volume":"11","author":"Gaballa","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.preteyeres.2025.101380_bib66","first-page":"2188","article-title":"Systemic immunosuppressive therapy for eye diseases cohort study","volume":"116","author":"Gangaputra","year":"2009","journal-title":"Methotrexate for ocular inflammatory diseases. Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib67","first-page":"1","article-title":"Janus kinase inhibitors as a third-line therapy for refractory endogenous noninfectious uveitis","author":"Garweg","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib68","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4161\/mabs.2.2.11271","article-title":"Certolizumab pegol","volume":"2","author":"Goel","year":"2010","journal-title":"mAbs"},{"key":"10.1016\/j.preteyeres.2025.101380_bib69","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0161-6420(01)00942-3","article-title":"Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation","volume":"109","author":"Goldstein","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib70","series-title":"Long-Term Follow-up of Patients Treated with short-term high-dose Chlorambucil for sight-threatening Ocular Inflammation 109","author":"Goldstein","year":"2002"},{"key":"10.1016\/j.preteyeres.2025.101380_bib71","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/09273948.2018.1491605","article-title":"Adalimumab in active and inactive, non-infectious uveitis: global results from the VISUAL I and VISUAL II trials","volume":"27","author":"Goto","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13075-017-1222-3","article-title":"Treatment of mucocutaneous manifestations in Beh\u00e7et\u2019s disease with anakinra: a pilot open-label study","volume":"19","author":"Grayson","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.preteyeres.2025.101380_bib73","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ophtha.2003.06.014","article-title":"Incidence and prevalence of uveitis in northern California; the northern California epidemiology of uveitis study","volume":"111","author":"Gritz","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib74","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4103\/0301-4738.194339","article-title":"Roles of interleukin-17 in uveitis","volume":"64","author":"Guedes","year":"2016","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib75","series-title":"Statpearls","article-title":"Rituximab","author":"Hanif","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib76","series-title":"Statpearls","article-title":"Methotrexate","author":"Hanoodi","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib77","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/09273948.2015.1133835","article-title":"Interferon Alpha-2a therapy in patients with refractory beh\u00e7et uveitis","volume":"25","author":"Hasanreisoglu","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105483","article-title":"Ophthalmic adverse events under tofacitinib and baricitinib: case analysis of the european pharmacovigilance database","volume":"90","author":"Hecquet","year":"2023","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.preteyeres.2025.101380_bib79","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/ker107","article-title":"Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (Rituximab)","volume":"50","author":"Heiligenhaus","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib80","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","article-title":"Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU):: the phase 2 SATURN study","volume":"126","author":"Heissigerov\u00e1","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib81","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-Associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib82","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/09273948.2024.2400165","article-title":"Frequency of HLA-B27 haplotype among patients with acute anterior uveitis and controls in Ethiopia","volume":"33","author":"Henok","year":"2025","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib83","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.ophtha.2007.01.026","article-title":"Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis","volume":"114","author":"Hogan","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib84","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41433-018-0223-z","article-title":"Noninfectious uveitis in the Asia\u2013Pacific region","volume":"33","author":"Hsu","year":"2019","journal-title":"Eye"},{"key":"10.1016\/j.preteyeres.2025.101380_bib85","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41435-022-00168-6","article-title":"Progress in the genetics of uveitis","volume":"23","author":"Huang","year":"2022","journal-title":"Genes Immun."},{"key":"10.1016\/j.preteyeres.2025.101380_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib87","series-title":"Pharmaceuticals. International Agency for Research on Cancer","article-title":"Chlorambucil","author":"Humans","year":"2012"},{"key":"10.1016\/j.preteyeres.2025.101380_bib88","author":"Iapoce"},{"key":"10.1016\/j.preteyeres.2025.101380_bib89","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1002\/cphg.95","article-title":"Genetic risk scores","volume":"104","author":"Igo","year":"2019","journal-title":"Curr. Protoc. Hum. Genet."},{"key":"10.1016\/j.preteyeres.2025.101380_bib91","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/annrheumdis-2020-218019","article-title":"Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs","volume":"79","author":"Isaacs","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib92","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2017.08.007","article-title":"Immunosuppression for the uveitides","volume":"125","author":"Jabs","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib93","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib94","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib95","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/09273948.2017.1332231","article-title":"Choroidal and retinal anatomical responses following systemic corticosteroid therapy in vogt-koyanagi-harada disease using swept-source optical coherence tomography","volume":"27","author":"Jaisankar","year":"2019","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2024.07.010","article-title":"Predictors of therapy success in weekly adalimumab for refractory uveitis: a retrospective cohort study","volume":"270","author":"Janetos","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib98","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13023-020-1324-x","article-title":"Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis","volume":"15","author":"Jari","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.740057","article-title":"TNF-\u03b1 in uveitis: from bench to clinic","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.695904","article-title":"Epidemiology and risk factors in non-infectious uveitis: a systematic review","volume":"8","author":"Joltikov","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib101","author":"Jordon"},{"key":"10.1016\/j.preteyeres.2025.101380_bib102","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2009.08.010","article-title":"Cyclosporine for ocular inflammatory diseases","volume":"117","author":"Ka\u00e7maz","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib103","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.intimp.2016.03.016","article-title":"Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis","volume":"35","author":"Kasama","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib104","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.ophtha.2014.03.006","article-title":"Objective measurement of vitreous inflammation using optical coherence tomography","volume":"121","author":"Keane","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/09286580701585892","article-title":"Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the systemic immunosuppressive therapy for eye diseases (SITE) cohort study","volume":"15","author":"Kempen","year":"2008","journal-title":"Ophthalmic Epidemiol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib106","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2480","article-title":"Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study","volume":"339","author":"Kempen","year":"2009","journal-title":"Br. Med. J."},{"key":"10.1016\/j.preteyeres.2025.101380_bib107","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ajo.2015.12.034","article-title":"Remission of intermediate uveitis: incidence and predictive factors","volume":"164","author":"Kempen","year":"2016","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib108","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2017.5103","article-title":"Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis","volume":"317","author":"Kempen","year":"2017","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.preteyeres.2025.101380_bib109","article-title":"Systemic immunosuppressive therapy for eye diseases cohort study research group","author":"Kempen","year":"2023","journal-title":"Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality. Ophthalmology S0161-6420"},{"key":"10.1016\/j.preteyeres.2025.101380_bib110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41577-023-00970-x","article-title":"Therapeutic induction of antigen-specific immune tolerance","volume":"24","author":"Kenison","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpbup.2024.100148","article-title":"Artificial intelligence for clinical prediction: exploring key domains and essential functions","volume":"5","author":"Khalifa","year":"2024","journal-title":"Comput. Methods Programs Biomed. Update"},{"key":"10.1016\/j.preteyeres.2025.101380_bib112","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.4103\/IJO.IJO_3223_23","article-title":"Efficacy of adalimumab in noninfectious pediatric uveitis: analysis of 29 eyes from a tertiary eye care center in India","volume":"72","author":"Khan","year":"2024","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib113","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/14712598.2025.2476030","article-title":"Optimizing biosimilar development: current approaches to demonstrating pharmacokinetic and analytical similarity and a proposal for a single reference approach","volume":"25","author":"Kiely","year":"2025","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101380_bib114","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2209920","article-title":"Izokibep: preclinical development and first-in-human study of a novel IL-17A neutralizing affibody molecule in patients with plaque psoriasis","volume":"15","author":"Klint","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.preteyeres.2025.101380_bib115","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.3390\/jcm11133606","article-title":"Comprehensive proteomic profiling of vitreous humor in ocular sarcoidosis compared with other vitreoretinal diseases","volume":"11","author":"Komatsu","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib116","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ophtha.2013.07.019","article-title":"Infliximab for the treatment of refractory noninfectious uveitis","volume":"121","author":"Kruh","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib117","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1093\/hmg\/ddu307","article-title":"A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathy","volume":"23","author":"Kuiper","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.preteyeres.2025.101380_bib118","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40265-018-0929-z","article-title":"Sarilumab: a review in moderate to severe rheumatoid arthritis","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.preteyeres.2025.101380_bib119","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/IAE.0000000000001563","article-title":"LONG-TERM outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy","volume":"38","author":"Lasave","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.preteyeres.2025.101380_bib120","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41746-022-00610-z","article-title":"Building digital twins of the human immune system: toward a roadmap","volume":"5","author":"Laubenbacher","year":"2022","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108084","article-title":"Excitable dynamics of flares and relapses in autoimmune diseases","volume":"26","author":"Lebel","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.preteyeres.2025.101380_bib122","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature14539","article-title":"Deep learning","volume":"521","author":"LeCun","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.preteyeres.2025.101380_bib123","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2022.901144","article-title":"Regulatory T cells: therapeutic opportunities in uveitis","volume":"2","author":"Lee","year":"2022","journal-title":"Front. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib124","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3341\/kjo.2012.26.1.21","article-title":"Clinical outcomes of cyclosporine treatment for noninfectious uveitis","volume":"26","author":"Lee","year":"2012","journal-title":"Korean J. Ophthalmol. KJO"},{"key":"10.1016\/j.preteyeres.2025.101380_bib125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3341\/kjo.2012.26.1.21","article-title":"Clinical outcomes of cyclosporine treatment for noninfectious uveitis","volume":"26","author":"Lee","year":"2012","journal-title":"Kor. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib126","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.10.12.27","article-title":"Challenges associated with ellipsoid zone intensity measurements using optical coherence tomography","volume":"10","author":"Lee","year":"2021","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib127","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2125.1999.00884.x","article-title":"Therapeutic drug monitoring of antimetabolic cytotoxic drugs","volume":"47","author":"Lennard","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib128","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib129","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jir.2018.0125","article-title":"Interferon alpha 2a and 2b in ophthalmology: a review. J. Interferon cytokine res. Off","volume":"39","author":"Lewczuk","year":"2019","journal-title":"J. Int. Soc. Interferon Cytokine Res."},{"key":"10.1016\/j.preteyeres.2025.101380_bib131","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/09286586.2021.1887285","article-title":"Treatment exit options for non-infectious uveitis (TOFU): study protocol for a prospective clinical registry","volume":"29","author":"Li","year":"2022","journal-title":"Ophthalmic Epidemiol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib132","first-page":"197","article-title":"Folate supplementation for methotrexate therapy in patients with rheumatoid arthritis: a systematic review","volume":"25","author":"Liu","year":"2019","journal-title":"J. Clin. Rheumatol. Pract. Rep. Rheum. Musculoskelet. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.784860","article-title":"Case report: a promising treatment strategy for noninfectious uveitis","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib134","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1080\/09273948.2021.1930063","article-title":"Efficacy of tacrolimus in uveitis, and the usefulness of serum tacrolimus levels in predicting disease control. Results from a single large center","volume":"30","author":"Luis","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib135","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/(SICI)1097-4547(19970801)49:3<268::AID-JNR2>3.0.CO;2-A","article-title":"Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown","volume":"49","author":"Luna","year":"1997","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.preteyeres.2025.101380_bib136","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/1744666X.2023.2207823","article-title":"Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis","volume":"19","author":"Maccora","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib137","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X241275822","article-title":"Uveitis in paediatric beh\u00e7et disease: a large multicentric Italian cohort","volume":"16","author":"Maccora","year":"2024","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib138","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cpt.3252","article-title":"Agreement about availability of alternative treatments for innovative drugs assessed by the EMA and HTA organizations","volume":"116","author":"Madrid Paredes","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.preteyeres.2025.101380_bib139","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/rheumatology\/kew486","article-title":"Exploring the variability in Beh\u00e7et\u2019s disease prevalence: a meta-analytical approach","volume":"57","author":"Maldini","year":"2018","journal-title":"Rheumatol. Oxf. Engl."},{"key":"10.1016\/j.preteyeres.2025.101380_bib140","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002693","article-title":"Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients","volume":"8","author":"Mart\u00edn-Varillas","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.preteyeres.2025.101380_bib142","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.oret.2017.07.016","article-title":"Predictors of recurrence in vogt-koyanagi-harada disease","volume":"2","author":"Maruyama","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"10.1016\/j.preteyeres.2025.101380_bib143","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4103\/0301-4738.58472","article-title":"Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance","volume":"58","author":"Mathews","year":"2010","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib144","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4161\/mabs.1.5.9286","article-title":"Golimumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.preteyeres.2025.101380_bib145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1759720X17752037","article-title":"Efficacy and safety of sarilumab in patients with active rheumatoid arthritis","volume":"10","author":"McCarty","year":"2018","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib147","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.preteyeres.2025.101380_bib149","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CM9.0000000000001050","article-title":"Application of single-cell sequencing in autoimmune diseases","volume":"134","author":"Mi","year":"2021","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.preteyeres.2025.101380_bib150","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ophtha.2010.07.031","article-title":"Rituximab for uveitis","volume":"118","author":"Miserocchi","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib151","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/ceo.13922","article-title":"Secukinumab in HLA-B27 associated uveitis","volume":"49","author":"Miserocchi","year":"2021","journal-title":"Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib152","series-title":"Statpearls","article-title":"Azathioprine","author":"Mohammadi","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib153","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial","volume":"121","author":"Morgan","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib154","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S2214-109X(22)00460-0","article-title":"Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities","volume":"11","author":"Morin","year":"2023","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.preteyeres.2025.101380_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1509805","article-title":"Integrative immunology identified interferome signatures in uveitis and systemic disease-associated uveitis","volume":"16","author":"Munhoz","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib156","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1001\/jama.2013.393","article-title":"The inevitable application of big data to health care","volume":"309","author":"Murdoch","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.preteyeres.2025.101380_bib157","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib158","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3109\/09273948.2011.606593","article-title":"Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis","volume":"19","author":"Muselier","year":"2011","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib159","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaad.2015.12.044","article-title":"High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: a population-based cohort study","volume":"74","author":"Na","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","article-title":"Filgotinib: a clinical pharmacology review","volume":"61","author":"Namour","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.preteyeres.2025.101380_bib161","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10792-025-03413-9","article-title":"Precision medicine in uveitis: redefining treatment optimization through biomarkers and tailored therapies","volume":"45","author":"Neri","year":"2025","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib162","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/ibd.20225","article-title":"Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents","volume":"13","author":"Nesbitt","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"issue":"CMT.S2218","key":"10.1016\/j.preteyeres.2025.101380_bib163","article-title":"A review of enteric-coated mycophenolate sodium for renal transplant immunosuppression","volume":"1","author":"Newbold","year":"2009","journal-title":"Clin. Med. Therapeut."},{"key":"10.1016\/j.preteyeres.2025.101380_bib164","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12348-021-00252-4","article-title":"Rituximab for non-infectious uveitis and scleritis","volume":"11","author":"Ng","year":"2021","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.preteyeres.2025.101380_bib165","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.preteyeres.2025.101380_bib166","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.preteyeres.2025.101380_bib167","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41540-024-00450-5","article-title":"Immune digital twins for complex human pathologies: applications, limitations, and challenges","volume":"10","author":"Niarakis","year":"2024","journal-title":"Npj Syst. Biol. Appl."},{"key":"10.1016\/j.preteyeres.2025.101380_bib168","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"10.1016\/j.preteyeres.2025.101380_bib169","unstructured":"Novartis Media Relations, n.d. FDA approves novartis cosentyx\u00ae as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade [WWW Document]. Novartis. URL https:\/\/www.novartis.com\/news\/media-releases\/fda-approves-novartis-cosentyx-first-new-biologic-treatment-option-hidradenitis-suppurativa-patients-nearly-decade (accessed 10.10.24)."},{"key":"10.1016\/j.preteyeres.2025.101380_bib170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0002-9394(14)76692-9","article-title":"Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis","volume":"112","author":"Nussenblatt","year":"1991","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib171","series-title":"Statpearls","article-title":"Cyclophosphamide","author":"Ogino","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib172","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et\u2019s disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib174","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.625710","article-title":"Genetics of beh\u00e7et\u2019s disease: functional genetic analysis and estimating disease heritability","volume":"8","author":"Ortiz-Fern\u00e1ndez","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib175","series-title":"Statpearls","article-title":"Tofacitinib","author":"Padda","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib176","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","article-title":"Tofacitinib for refractory uveitis and scleritis","volume":"13","author":"Paley","year":"2018","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"10.1016\/j.preteyeres.2025.101380_bib177","series-title":"Statpearls","article-title":"Etanercept","author":"Pan","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib178","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1097\/MS9.0000000000001320","article-title":"Artificial intelligence (AI) in personalized medicine: AI-Generated personalized therapy regimens based on genetic and medical history: short communication","volume":"85","author":"Parekh","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.preteyeres.2025.101380_bib179","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib180","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib181","article-title":"Intravitreal interleukin-6 inhibition with vamikibart in sarcoidosis-associated uveitis","volume":"65","author":"Pauly-Evers","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"23","key":"10.1016\/j.preteyeres.2025.101380_bib182","article-title":"The humira in ocular inflammations taper (HOT) study","volume":"S0002\u20139394","author":"Pichi","year":"2023","journal-title":"Am. J. Ophthalmol."},{"issue":"Suppl. 6","key":"10.1016\/j.preteyeres.2025.101380_bib183","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2105-14-S6-S7","article-title":"On the computational modeling of the innate immune system","volume":"14","author":"Pigozzo","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.preteyeres.2025.101380_bib184","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/09273948.2019.1687733","article-title":"Visual acuity outcome over time in non-infectious uveitis","volume":"29","author":"Pistilli","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib185","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.berh.2014.10.005","article-title":"Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis","volume":"28","author":"Poddubnyy","year":"2014","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib186","series-title":"Statpearls","article-title":"Tocilizumab","author":"Preuss","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib187","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ophtha.2009.06.060","article-title":"Cyclophosphamide for ocular inflammatory diseases","volume":"117","author":"Pujari","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib188","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.699903","article-title":"Comparison of the safety and efficacy of interferon Alpha-2a and Cyclosporine-A when combined with glucocorticoid in the treatment of refractory beh\u00e7et\u2019s uveitis: a randomized controlled prospective study","volume":"12","author":"Qian","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib189","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","article-title":"ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis","volume":"77","author":"Quartier","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib190","article-title":"Onset of spondyloarthritis in a patient treated with adalimumab for relapsing anterior uveitis \u2013 efficacy of secukinumab on the joint domain and on ocular inflammatory relapses: a case report","volume":"101","author":"Raimondo","year":"2022","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.preteyeres.2025.101380_bib191","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","article-title":"Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis","volume":"376","author":"Ramanan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib192","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0010-2","article-title":"A phase II trial protocol of tocilizumab in anti-TNF refractory patients with JIA-Associated uveitis (the APTITUDE trial)","volume":"2","author":"Ramanan","year":"2018","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib193","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S2665-9913(20)30008-4","article-title":"Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial","volume":"2","author":"Ramanan","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib194","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/bjo.2010.182311","article-title":"Population-based prevalence of uveitis in southern India","volume":"95","author":"Rathinam","year":"2011","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib195","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jama.2019.12618","article-title":"Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial","volume":"322","author":"Rathinam","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.preteyeres.2025.101380_bib196","author":"Reddy"},{"key":"10.1016\/j.preteyeres.2025.101380_bib197","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10792-020-01647-3","article-title":"Vogt-koyanagi-harada disease in a Native American population in Oklahoma","volume":"41","author":"Reddy","year":"2021","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib198","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in Male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies","volume":"82","author":"Reinisch","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib200","unstructured":"Restaysis [WWW Document], n.d. URL Restaysis."},{"key":"10.1016\/j.preteyeres.2025.101380_bib201","article-title":"Azathioprine for people with multiple sclerosis","author":"Ridley","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.preteyeres.2025.101380_bib202","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/iovs.65.13.29","article-title":"Potential prognostic protein biomarkers in tears from noninfectious uveitis patients under biologic treatment as a prelude to personalized medicine","volume":"65","author":"Rodr\u00edguez-Mart\u00ednez","year":"2024","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.preteyeres.2025.101380_bib203","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1080\/09273948.2022.2113800","article-title":"Multiple sclerosis in a patient with intermediate uveitis and juvenile idiopathic arthritis treated with adalimumab: a case report","volume":"31","author":"Rojas-Carabali","year":"2023","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib204","article-title":"Managing a patient with uveitis in the era of artificial intelligence: current approaches, emerging trends, and future perspectives","volume":"13","author":"Rojas-Carabali","year":"2024","journal-title":"Asia-Pac. J. Ophthalmol. Phila. Pa"},{"key":"10.1016\/j.preteyeres.2025.101380_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103497","article-title":"Vitamin D deficiency and non-infectious uveitis: a systematic review and meta-analysis","volume":"23","author":"Rojas-Carabali","year":"2024","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.preteyeres.2025.101380_bib206","article-title":"Programme for ocular inflammation & infection translational research (PROTON) registry: cross-Sectional analysis of baseline patient characteristics","volume":"14","author":"Rojas-Carabali","year":"2025","journal-title":"Asia-Pac. J. Ophthalmol. Phila. Pa"},{"key":"10.1016\/j.preteyeres.2025.101380_bib207","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2013.02.002","article-title":"Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies","volume":"12","author":"Saadoun","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.preteyeres.2025.101380_bib208","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.preteyeres.2025.101380_bib209","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0161-6420(01)00576-0","article-title":"Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients","volume":"108","author":"Samson","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib210","series-title":"Carcinogenicity of Anticancer Drugs and Especially Alkylating Agents","first-page":"29","author":"Schm\u00e4hl","year":"1986"},{"key":"10.1016\/j.preteyeres.2025.101380_bib211","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","article-title":"Etanercept and uveitis in patients with juvenile idiopathic arthritis","volume":"44","author":"Schmeling","year":"2005","journal-title":"Rheumatol. Oxf. Engl."},{"key":"10.1016\/j.preteyeres.2025.101380_bib212","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et\u2019s disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.preteyeres.2025.101380_bib213","doi-asserted-by":"crossref","first-page":"404","DOI":"10.7326\/0003-4819-140-5-200403020-00025","article-title":"Infliximab for recurrent, sight-threatening ocular inflammation in adamantiades-beh\u00e7et disease","volume":"140","author":"Sfikakis","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib214","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/MS9.0000000000000546","article-title":"Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal","volume":"85","author":"Sharma","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.preteyeres.2025.101380_bib215","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01375-y","article-title":"Synthetic data boosts medical foundation models","author":"Sheng","year":"2025","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.preteyeres.2025.101380_bib216","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1001\/jamaophthalmol.2017.0603","article-title":"Effect of adalimumab on visual functioning in patients with noninfectious intermediate uveitis, posterior uveitis, and panuveitis in the VISUAL-1 and VISUAL-2 trials","volume":"135","author":"Sheppard","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib217","article-title":"Vitamin D supplementation and remission from chronic anterior uveitis","volume":"1\u20134","author":"Shih","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib218","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12969-023-00841-8","article-title":"Encouraging visual outcomes in children with idiopathic and JIA associated uveitis: a population-based study","volume":"21","author":"Siiskonen","year":"2023","journal-title":"Pediatr. Rheumatol. Online J."},{"key":"10.1016\/j.preteyeres.2025.101380_bib219","series-title":"Statpearls","article-title":"Primary intraocular lymphoma","author":"Simakurthy","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib220","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.37776","article-title":"Clinical and transcriptional response to the long\u2010acting interleukin\u20101 blocker canakinumab in blau syndrome\u2013related uveitis","volume":"65","author":"Simonini","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.preteyeres.2025.101380_bib221","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/acr.22214","article-title":"Current evidence of anti-tumor necrosis factor \u03b1 treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs","volume":"66","author":"Simonini","year":"2014","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.preteyeres.2025.101380_bib222","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-alpha therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm. World Sci. PWS"},{"key":"10.1016\/j.preteyeres.2025.101380_bib223","series-title":"Proceedings of the 38th ACM\/SIGAPP Symposium on Applied Computing, SAC \u201923","first-page":"559","article-title":"A synthetic dataset generation for the uveitis pathology based on MedWGAN model","author":"Sliman","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib224","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo\u2010controlled, double\u2010masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.preteyeres.2025.101380_bib225","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/art.20904","article-title":"A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis","volume":"53","author":"Smith","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.preteyeres.2025.101380_bib226","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","article-title":"Safety and effectiveness of interferon Alpha-2a in treatment of patients with beh\u00e7et\u2019s uveitis refractory to conventional treatments","volume":"117","author":"Sobac\u0131","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib227","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ophtha.2019.11.020","article-title":"Factors predictive of remission of chronic anterior uveitis","volume":"127","author":"Sobrin","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib228","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10384-020-00809-1","article-title":"Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey","volume":"65","author":"Sonoda","year":"2021","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib229","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40674-017-0057-z","article-title":"An update on treatment of pediatric chronic non-infectious uveitis","volume":"3","author":"Sood","year":"2017","journal-title":"Curr. Treat. Options Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib230","article-title":"FDA approves intravenous cosentyx","year":"2023","journal-title":"Spondylitis Assoc. Am. - Ankyl. Spondylitis. URL"},{"key":"10.1016\/j.preteyeres.2025.101380_bib231","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.exer.2008.03.012","article-title":"Focus on molecules: nuclear Factor-kappaB","volume":"88","author":"Srivastava","year":"2008","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.preteyeres.2025.101380_bib232","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib233","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.preteyeres.2025.101380_bib234","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41746-020-0229-3","article-title":"A systematic review of the applications of artificial intelligence and machine learning in autoimmune diseases","volume":"3","author":"Stafford","year":"2020","journal-title":"npj Digit. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib235","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/jpm13030380","article-title":"Personalised medicine\u2014implementation to the healthcare system in Europe (focus group discussions)","volume":"13","author":"Stefanicka-Wojtas","year":"2023","journal-title":"J. Personalized Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib236","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of Infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib237","first-page":"819","article-title":"Infliximab therapy for refractory uveitis: 2-Year results of a prospective trial","volume":"127","author":"Suhler","year":"2009","journal-title":"Arch. Ophthalmol. Chic. Ill 1960"},{"key":"10.1016\/j.preteyeres.2025.101380_bib238","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/j.ophtha.2014.04.044","article-title":"Rituximab therapy for refractory scleritis: results of a phase I\/II dose-ranging, randomized, clinical trial","volume":"121","author":"Suhler","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib239","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.ophtha.2017.12.039","article-title":"Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: visual III","volume":"125","author":"Suhler","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib240","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ophtha.2020.10.036","article-title":"Long-term safety and efficacy of adalimumab in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis","volume":"128","author":"Suhler","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib241","article-title":"Reduced dose methotrexate and mycophenolate mofetil in noninfectious uveitis: a sub-analysis from the first-line antimetabolites as steroid sparing therapy (FAST) trial","author":"Sura","year":"2023","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib242","article-title":"TCR-H: explainable machine learning prediction of T-cell receptor epitope binding on unseen datasets","volume":"15","author":"T Rajeshwar","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib243","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640473","article-title":"Pathogenesis of non-infectious uveitis elucidated by recent genetic findings","volume":"12","author":"Takeuchi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib244","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1095423","article-title":"Ten-year follow-up of infliximab treatment for uveitis in beh\u00e7et disease patients: a multicenter retrospective study","volume":"10","author":"Takeuchi","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib245","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s41669-024-00491-w","article-title":"Impact of value-driven healthcare strategies for biosimilar adoption: the Singapore story","volume":"8","author":"Tan","year":"2024","journal-title":"PharmacoEconomics - Open"},{"key":"10.1016\/j.preteyeres.2025.101380_bib246","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1080\/09273948.2024.2359621","article-title":"Beyond Pathology- exploring salutogenesis as a novel approach to eye inflammatory disease prevention and management: a perspective","volume":"32","author":"Tan Yip Ming","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib247","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1080\/09273948.2024.2337836","article-title":"Unveiling key pathological indicators for disease progression in vogt koyanagi harada disease and sympathetic ophthalmia through advanced choroidal volume analysis","volume":"32","author":"Tanikawa","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib248","series-title":"Statpearls","article-title":"Cyclosporine","author":"Tapia","year":"2023"},{"key":"10.1016\/j.preteyeres.2025.101380_bib249","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000103239","article-title":"Rituximab as a treatment option for refractory endogenous anterior uveitis","volume":"39","author":"Tappeiner","year":"2007","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.preteyeres.2025.101380_bib250","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ophtha.2008.10.033","article-title":"Intraocular methotrexate in the treatment of Uveitis and uveitic Cystoid macular edema","volume":"116","author":"Taylor","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.preteyeres.2025.101380_bib251","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.ajo.2008.03.004","article-title":"Mycophenolate mofetil for the treatment of uveitis","volume":"146","author":"Teoh","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib252","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","article-title":"Mode of action of tacrolimus (FK506): molecular and cellular mechanisms","volume":"17","author":"Thomson","year":"1995","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.preteyeres.2025.101380_bib253","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/jamaophthalmol.2016.3229","article-title":"Prevalence of noninfectious uveitis in the United States: a claims-based analysis","volume":"134","author":"Thorne","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib254","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1136\/bjophthalmol-2018-313173","article-title":"Artificial intelligence and deep learning in ophthalmology","volume":"103","author":"Ting","year":"2019","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib255","first-page":"109","article-title":"Can rituximab induce long-term disease remission in patients with intra-ocular non-infectious inflammation? Ophthalmol","volume":"230","author":"Tomkins-Netzer","year":"2013","journal-title":"J. Int. Ophtalmol. Int. J. Ophthalmol. Z. Augenheilkd."},{"key":"10.1016\/j.preteyeres.2025.101380_bib256","first-page":"680","article-title":"Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis","volume":"37","author":"Tosi","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib257","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib258","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3109\/09273948.2015.1092558","article-title":"Safety and efficacy of gevokizumab in patients with beh\u00e7et\u2019s disease uveitis: results of an exploratory phase 2 Study","volume":"25","author":"Tugal-Tutkun","year":"2017","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib259","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/09273948.2017.1421233","article-title":"Use of gevokizumab in patients with beh\u00e7et\u2019s disease uveitis: an international, randomized, Double-Masked, placebo-controlled Study and open-label extension Study","volume":"26","author":"Tugal-Tutkun","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib260","article-title":"Update on non-infectious uveitis treatment: anti-tnf-alpha and beyond","volume":"4","author":"Tyagi","year":"2024","journal-title":"Front. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib261","article-title":"Efficacy and safety of tocilizumab in the management of non-infectious uveitis failed with conventional immunomodulatory and Anti-TNF\u03b1 therapies","author":"Uludag","year":"2022","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib262","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s10384-022-00923-2","article-title":"Use of systemic corticosteroids in patients newly registered at a claims database with a diagnosis of non-infectious uveitis: results from a real-world claims database analysis","volume":"66","author":"Umazume","year":"2022","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib263","series-title":"IMURAN \u00ae (Azathioprine)","year":"2018"},{"key":"10.1016\/j.preteyeres.2025.101380_bib264","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40273-023-01244-z","article-title":"Filgotinib for treating moderately to severely active ulcerative Colitis: an Evidence Review Group perspective of a NICE single technology appraisal","volume":"41","author":"van Asselt","year":"2023","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.preteyeres.2025.101380_bib265","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1080\/09273948.2023.2229900","article-title":"Long-Term Follow-Up of patients with scleritis after Rituximab treatment including B cell monitoring","volume":"32","author":"van Bilsen","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib266","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001161","article-title":"The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW","volume":"6","author":"van der Horst-Bruinsma","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.preteyeres.2025.101380_bib267","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001161","article-title":"The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW","volume":"6","author":"van der Horst-Bruinsma","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.preteyeres.2025.101380_bib268","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamaophthalmol.2015.5934","article-title":"Precision medicine: personalized proteomics for the diagnosis and treatment of idiopathic inflammatory disease","volume":"134","author":"Velez","year":"2016","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib269","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2022.100258","article-title":"SynthEye: investigating the impact of synthetic data on artificial intelligence-assisted gene diagnosis of inherited retinal disease","volume":"3","author":"Veturi","year":"2023","journal-title":"Ophthalmol. Sci."},{"key":"10.1016\/j.preteyeres.2025.101380_bib270","article-title":"Efficacy and safety of janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries","volume":"11","author":"Vitale","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib271","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/jamia\/ocx079","article-title":"Synthea: an approach, method, and software mechanism for generating synthetic patients and the synthetic electronic health care record","volume":"25","author":"Walonoski","year":"2018","journal-title":"J. Am. Med. Inform. Assoc. JAMIA"},{"key":"10.1016\/j.preteyeres.2025.101380_bib272","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/singaporemedj.SMJ-2023-243","article-title":"N-of-1 medicine","volume":"65","author":"Wang","year":"2024","journal-title":"Singap. Med. J."},{"key":"10.1016\/j.preteyeres.2025.101380_bib273","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf252","article-title":"Single-cell transcriptome analysis profiles cellular and molecular alterations in aortic tissue from patients with Beh\u00e7et\u2019s syndrome","author":"Wang","year":"2025","journal-title":"Rheumatol. Oxf. Engl. keaf252"},{"key":"10.1016\/j.preteyeres.2025.101380_bib274","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5114\/ko.2019.84562","article-title":"Does the beneficial effect of mycophenolate mofetil persist long-term in the treatment of non-infectious uveitis?","volume":"2019","author":"Waszczyk-\u0141aczak","year":"2019","journal-title":"Klin. Oczna"},{"key":"10.1016\/j.preteyeres.2025.101380_bib275","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12967-023-04228-x","article-title":"Comprehensive profiling of extracellular vesicles in uveitis and scleritis enables biomarker discovery and mechanism exploration","volume":"21","author":"Wu","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib276","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10238-022-00954-6","article-title":"Pathogenesis and current therapies for non-infectious uveitis","volume":"23","author":"Wu","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.preteyeres.2025.101380_bib277","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/jamadermatol.2022.3337","article-title":"Association between low-dose methotrexate exposure and melanoma: a systematic review and meta-analysis","volume":"158","author":"Yan","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib278","first-page":"813","article-title":"Intracellular signaling mechanisms underlying the expression of pro-inflammatory mediators in airway diseases","volume":"28","author":"Yang","year":"2005","journal-title":"Chang Gung Med. J."},{"key":"10.1016\/j.preteyeres.2025.101380_bib279","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10792-016-0239-y","article-title":"Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis","volume":"37","author":"Yazgan","year":"2017","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.preteyeres.2025.101380_bib280","doi-asserted-by":"crossref","DOI":"10.3389\/fdgth.2022.830656","article-title":"N-of-1 healthcare: challenges and prospects for the future of personalized medicine","volume":"4","author":"You","year":"2022","journal-title":"Front. Digit. Health"},{"key":"10.1016\/j.preteyeres.2025.101380_bib281","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1080\/09273948.2022.2140062","article-title":"Uveitis registries - a digital tool for patient care, education, research, and collaboration","volume":"31","author":"Zhang","year":"2023","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib282","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1080\/09273948.2023.2247077","article-title":"Psychosocial well-being and quality of life in uveitis: a review","volume":"32","author":"Zhang","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.preteyeres.2025.101380_bib283","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1167\/iovs.64.5.24","article-title":"Identification of Hif1\u03b1 as a potential participant in autoimmune uveitis pathogenesis using single-cell transcriptome analysis","volume":"64","author":"Zhu","year":"2023","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Progress in Retinal and Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946225000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1350946225000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T19:01:16Z","timestamp":1762369276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1350946225000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":278,"alternative-id":["S1350946225000539"],"URL":"https:\/\/doi.org\/10.1016\/j.preteyeres.2025.101380","relation":{},"ISSN":["1350-9462"],"issn-type":[{"value":"1350-9462","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunomodulatory therapy in non-infectious Uveitis: Current landscape, gaps, and future directions","name":"articletitle","label":"Article Title"},{"value":"Progress in Retinal and Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.preteyeres.2025.101380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101380"}}